Piezo Therapeutics, Inc.

Startup

About Piezo Therapeutics

Piezo Therapeutics is a spinout from Georgia Tech focused on enabling next-gen nucleic acid vaccines and therapeutics via formulation-free delivery. Integrating innovations in drug delivery and genetic medicine, Piezo is advancing its delivery platform and investigational therapeutics in collaboration with global pharma and biotech companies to prevent and treat debilitating diseases. The company raised its initial financing in 2023 backed by Good Ventures. For more information, please visit www.piezotx.com.

About Piezopen Platform

Our proprietary Piezopen platform enables localized yet highly efficient delivery of RNA and DNA without the need for lipid nanoparticles or viral vectors, with applications in infectious disease, cancer, chronic disease, and dermatology. In preclinical models, we have demonstrated robust induction of humoral and cellular responses to infectious disease and cancer vaccines with increased tolerability, dosing flexibility, and payload versatility. In human subjects, Piezopen was well accepted and shown to elicit superior tolerability compared to a hypodermic needle. Piezopen combines two innovations to surpass the limitations of formulations: piezoelectric pulses and microelectrodes for skin-targeted "naked" nucleic acid delivery. Piezopen improves the tolerability and efficacy of RNA/DNA medicines while slashing costs, simplifying manufacturing, and transforming scalability.

website